5470 Louie Lane, Suite 101
Reno, NV 89511

(775) 851-3337
(775) 851-3363 Fax
www.carbonbased.com

Anna

Test date: 1/8/1999

Next Test Due: 12/27/2004

CellMate™ Fatty Acids Report

Practitioner

Printed on Friday, July 23, 2004 for:

Anna

If there is a problem with this report, please contact us as soon as possible at: (775) 851-3337 or Fax (775) 851-3363

Basic Status High/Low

Anna **Fatty Acids Date: 1/8/1999**

Female / Age: 46

Client ID:555986644 (8322)

The % Status is the weighted deviation of the laboratory result.

Low Results



	% Status		Result	*Low*	*High*
Dimorphecolic C18:2w3t	-50.00	**L**	**0.04**	0.04	0.28
Pentadecanoic C15:0	-50.00	**L**	**0.08**	0.08	0.16
Transvaccenic C18:1w7t	-38.94	**L**	**0.20**	-0.03	2.05
Heptadecanoic C17:0	-33.33	**L**	**0.29**	0.25	0.49
Linoleic C18:2w6	-25.00	**L**	**8.40**	6.43	14.31
11-Eicosenoic C20:1w9	-25.00	**L**	**0.00**	-0.03	0.09
Pristanic	-25.00	**L**	**0.03**	0.01	0.09
Linolelaidic C18:2w6t	-25.00	**L**	**0.07**	0.04	0.16

High Results



	% Status		Result	*Low*	*High*
18:1 DMA	162.50	**H**	**0.88**	0.37	0.61
Hexacosanoic C26:0	104.17	**H**	**0.38**	0.01	0.25
Nervonic C24:1w9	71.43	**H**	**4.51**	1.79	4.03
Mead C20:3w9	62.50	**H**	**0.15**	0.06	0.14
Eicosanoic C20:1w7	50.00	**H**	**0.21**	0.05	0.21
Behenic C22:0	39.42	**H**	**1.79**	0.86	1.90
Caproleic C10:1	37.50	**H**	**0.05**	-0.02	0.06
Arachidonic C20:4w6	37.01	**H**	**16.93**	11.57	17.73
Dihomo-y Lino. C20:3w6	28.57	**H**	**1.83**	0.95	2.07
Erucic C22:1w9	25.00	**H**	**0.07**	0.04	0.08
Phytanic	25.00	**H**	**0.06**	0.00	0.08
Tridecanoic C13:0	25.00	**H**	**0.02**	-0.01	0.03

Basic Status Alphabetic

Anna

Female / Age: 46

Fatty Acids Date: 1/8/1999

The % Status is the weighted deviation of the laboratory result relative to the range.



	% Status		Result	Low	High
11-Eicosenoic C20:1w9	**-25.00**	**L**	**0.00**	-0.03	0.09
18:0 DMA	-11.21		2.32	1.87	3.03
18:1 DMA	**162.50**	**H**	**0.88**	0.37	0.61
Alpha Linolenic C18:3w3	-6.25		0.28	0.14	0.46
Arachidic C20:0	-8.33		0.33	0.23	0.47
Arachidonic C20:4w6	**37.01**	**H**	**16.93**	11.57	17.73
Behenic C22:0	**39.42**	**H**	**1.79**	0.86	1.90
Capric C10:0	0.00		0.00	-0.02	0.02
Caproleic C10:1	**37.50**	**H**	**0.05**	-0.02	0.06
Dihomo-y Lino. C20:3w6	**28.57**	**H**	**1.83**	0.95	2.07
Dimorphecolic C18:2w3t	**-50.00**	**L**	**0.04**	0.04	0.28
Docosadienoic C22:2w6	3.03		3.15	1.75	4.39
Docosahexa. C22:6w3	7.24		3.77	1.16	5.72
Docosapenta. C22:5w3	-19.55		1.55	0.88	3.08
Docosapenta. C22:5w6	13.39		0.68	-0.03	1.09
Eicosadienoic C20:2w6	-18.75		0.22	0.17	0.33
Eicosanoic C20:1w7	**50.00**	**H**	**0.21**	0.05	0.21
Eicosapenta. C20:5w3	-19.12		0.32	0.11	0.79
Elaidic C18:1w9t	17.39		0.54	-0.08	0.84
Erucic C22:1w9	**25.00**	**H**	**0.07**	0.04	0.08
Gamma Linolenic C18:3w6	-12.50		0.05	-0.04	0.20
Heptadecanoic C17:0	**-33.33**	**L**	**0.29**	0.25	0.49
Hexacosanoic C26:0	**104.17**	**H**	**0.38**	0.01	0.25
Lauric C12:0	0.00		0.00	-0.02	0.02
Lignoceric C24:0	16.79		3.55	1.76	4.44
Linoleic C18:2w6	**-25.00**	**L**	**8.40**	6.43	14.31
Linolelaidic C18:2w6t	**-25.00**	**L**	**0.07**	0.04	0.16
Mead C20:3w9	**62.50**	**H**	**0.15**	0.06	0.14
Myristic C14:0	-21.88		0.21	0.12	0.44
Myristoleic C14:1w5	8.33		0.14	0.00	0.24
Nervonic C24:1w9	**71.43**	**H**	**4.51**	1.79	4.03
Nonadecanoic C19:0	-16.67		0.06	0.02	0.14
Oleic C18:1w9	-19.90		10.15	8.91	13.03
Palmitelaidic C16:1w7t	10.71		0.19	0.02	0.30
Palmitic C16:0	-10.26		16.71	15.20	19.00
Palmitoleic C16:1w7	-14.13		0.23	-0.10	0.82
Pentadecanoic C15:0	**-50.00**	**L**	**0.08**	0.08	0.16
Phytanic	**25.00**	**H**	**0.06**	0.00	0.08
Pristanic	**-25.00**	**L**	**0.03**	0.01	0.09
Stearic C18:0	-7.80		14.32	12.75	16.47
Transvaccenic C18:1w7t	**-38.94**	**L**	**0.20**	-0.03	2.05
Tricosanoic C23:0	-5.00		0.21	0.12	0.32
Tridecanoic C13:0	**25.00**	**H**	**0.02**	-0.01	0.03
Vaccenic C18:1w7	-8.33		0.98	0.78	1.26
Total Status Deviation	**27.66**				
Total Status Skew	**6.21**				

Anna **Fatty Acids Date: 1/8/1999**

Female / Age: 46

Nutritional Support

The following supplements may help to balance your biochemistry. Consult your practitioner.

- ☐ **1-B-Complex**
  2x daily 1 tablet
- ☐ **1-Incr. Protein to CHO Ratio**
  30% Pro, 30% Fat, 40% CHO
- ☐ **1-Reduce Red Meat Intake**
- ☐ **2-CoEnzyme Q10**
  2x daily 50 mg
- ☐ **2-Selenium**
  1x daily 200 mcg
- ☐ **2-Taurine**
  2x daily 400 mg

Food Recommendations

The following foods may help to balance or strengthen your biochemistry.

Grape Seed Oil, Mushrooms, Olive Oil, Rapeseed or Mustard Seed Oil, Spinach, Walnut Oil

Foods to AVOID

The following foods may aggravate already out-of-balance biochemistry.

Hydrogenated Fats, Phytanic Acid

Anna **Fatty Acids Date: 1/8/1999**

Female / Age: 46

Results Missing From Test

A more comprehensive report would have been generated if the following results were provided.

Heneicosanoic C21:0 Docosatetraenoic C22:4w6

Out-Of-Balance Panel Values

The following panels have a PSD of greater than 25% indicating need for further review. PSD is the Panel Status Deviation, or the average imbalance of that subset of results. The PSS is the Panel Status Skew, or the direction, negative (deficiency) or positive (excess), of that subset of results.

Panel Name	PSD	PSS
Very Long Chains	36.07%	29.94%
Neurochem Stability	36.06%	36.06%
Gluconeogenesis	35.92%	20.67%
Liver Function	35.28%	28.26%
Monounsaturates	27.77%	10.92%

Lab Reported out-of-range Values

The following results are out-of-range (as reported by the lab), and should be carefully reviewed.

18:1 DMA (162.50%)

Hexacosanoic C26:0 (104.17%)

Along with lignoceric and behenic acids, behenic acid is important in determining the progression of certain degenerative diseases. A high reading may be due to the lack of certain enzymes needed to avoid accumulation of these fatty acids.

Nervonic C24:1w9 (71.43%)

Mead C20:3w9 (62.50%)

Dimorphecolic C18:2w3t (-50.00%)

Eicosanoic C20:1w7 (50.00%)

Pentadecanoic C15:0 (-50.00%)

According to research, an accumulation of this fatty acid along with heptadecanoic and nonadecanoic acids may be indicative of general nutrient deficiencies.

Anna **Fatty Acids Date: 1/8/1999**

Female / Age: 46

Nutritional and herbal information contained in this report is based upon research related to imbalances in your chemistry. The recommendations are based upon the information provided, without interpretation. This must be done with the help of a qualified health care professional.

1-B-Complex 2x daily 1 tablet

Rationale

B-COMPLEX VITAMINS

B complex vitamins are involved in a broad spectrum of cell metabolic deficiencies as well as fatty acid utilization.

Decreased	Normal	Increased
		Arachidonic C20:4w6

1-Incr. Protein to CHO Ratio 30% Pro, 30% Fat, 40% CHO

INCREASE PROTEIN TO CHO RATIO

The increase in protein to carbohydrate ratio is essential to stabilizing fatty acid metabolism and insulin resistance.abnormal ratios may suppres delta 6 desaturates creating pro-inflammatory prostaglandins.

Decreased	Normal	Increased
		Arachidonic C20:4w6

1-Reduce Red Meat Intake

Red meat is high in the pro-inflammatory arachidonic acid. Excessive arachidonic acid can lead to over production of series 2 prostaglandins.

Decreased	Normal	Increased
		Arachidonic C20:4w6

2-CoEnzyme Q10 2x daily 50 mg

COENZYME Q10

Key electron shuttle in mitochondrial electron transport. Essential to cellular respiration. Effective in improving cardiac output and pulmonary function.

Decreased	Normal	Increased
	Stearic C18:0	Arachidonic C20:4w6

2-Selenium 1x daily 200 mcg

SELENIUM

A potent antioxidant, selenium has shown great promise as a cofactor in glutathione peroxidase, in detoxification of peroxides, free radicals control and thyroid hormone deionases.

Decreased	Normal	Increased
		Erucic C22:1w9

2-Taurine 2x daily 400 mg

TAURINE

A neuroinhibitory amino acid, it also mediates contractility in the cardiac muscle as well as being essential in the metabolism of fatty acids. Studies done in Italy (Cantaflora, Blotta, et al, 1991) show that deficiencies in taurine have been found with high nervonic acid levels and that supplementation is helpful.

Decreased	Normal	Increased
	Lignoceric C24:0	Nervonic C24:1w9

Anna **Fatty Acids Date: 1/8/1999**

Female / Age: 46

Drugs listed below tend to further aggravate elements of blood chemistry that are out of range (H or L). The (#) after each drug denotes the number of times that drug is flagged as being potentially harmful.

Anna
Female / Age: 46

Fatty Acids Date: 1/8/1999

Cardiac Risk

Linoleic C18:2w6[L], Alpha Linolenic C18:3w3, Gamma Linolenic C18:3w6, Dihomo-y Lino. C20:3w6[H], Arachidonic C20:4w6[H], Eicosapenta. C20:5.

This panel profile is indicative of a lowered risk of coronary heart disease.



Gluconeogenesis

Palmitoleic C16:1w7, Gamma Linolenic C18:3w6, Dihomo-y Lino. C20:3w6[H], Arachidonic C20:4w6[H], Eicosapenta. C20:5w3, Hexacosanoic C26:0[H].

A panel profile such as this may be indicative of a compromised ability to regulate insulin and glucose levels. Symptoms may include irritability, hypoglycemic reactions and mood swings.



Immune Status

Linoleic C18:2w6[L], Alpha Linolenic C18:3w3, Gamma Linolenic C18:3w6, Dihomo-y Lino. C20:3w6[H], Arachidonic C20:4w6[H], Eicosapenta. C20:5.

The profile seen in this panel may indicate a properly functioning immune system.



Inflammatory Proc

Oleic C18:1w9, Gamma Linolenic C18:3w6, Dihomo-y Lino. C20:3w6[H], Arachidonic C20:4w6[H], Docosapenta. C22:5w3, Lignoceric C24:0.

Thie panel profile is indicative of the lack of an ongoing inflammatory process, especially if the arachidonic acid is either low or normal.



Liver Function

Arachidonic C20:4w6[H], Behenic C22:0[H], Erucic C22:1w9[H], Docosapenta. C22:5w3, Tricosanoic C23:0, Lignoceric C24:0, Hexacosanoic C26:0[H.

This panel is indicative with compromised liver function. Improving healthy fatty acid intake by following the nutritional recommendations in the detail section is important.



Monounsaturates

Myristoleic C14:1w5, Palmitoleic C16:1w7, Vaccenic C18:1w7, Oleic C18:1w9, Eicosanoic C20:1w7[H], 11-Eicosenoic C20:1w9[L], Erucic C22:1w9[H.

The panel profile seen here may be indicative of the presence of a high level of monosaturated fatty acids (MUFA). Oils such as olive, palm and canola are high in MUFA's, especially oleic acid. Too many MUFA's can interfere with the processing of other fatty acids and prostaglandins.



Anna **Fatty Acids Date: 1/8/1999**

Female / Age: 46

Neurochem Stability

Dihomo-y Lino. C20:3w6[H], Arachidonic C20:4w6[H], Docosahexa. C22:6w3, Nervonic C24:1w9[H].

The profile in this panel may be indicative of neurochemical instability. Balancing co-factors and precurors such as B-complex vitamins and trace minerals may be called for.



Omega 3/Polys

Alpha Linolenic C18:3w3, Eicosapenta. C20:5w3, Docosapenta. C22:5w3, Docosahexa. C22:6w3.

This panel profile is consistant with adequate and balanced supplies of essential Omega 3 fatty acids. Zinc deficiency, alcoholism, obesity and aging can negatively effect this panel.



Omega 6/Polys

Linoleic C18:2w6[L], Gamma Linolenic C18:3w6, Dihomo-y Lino. C20:3w6[H], Arachidonic C20:4w6[H].

This panel profile is consistant with adequate and balanced supplies of essential Omega 6 fatty acids. Zinc deficiency, alcoholism, obesity and aging can also negatively effect this panel.



Very Long Chains

Behenic C22:0[H], Erucic C22:1w9[H], Docosapenta. C22:5w3, Docosahexa. C22:6w3, Tricosanoic C23:0, Lignoceric C24:0, Nervonic C24:1w9[H], He.

The profile in this panel may indicate the inability of the body to properly breakdown long chain fatty acids as well as a disruption in other fatty acid cascades. Supplementation with trace minerals, B-Complex vitamins and a broad spectrum of amino acids may be helpful.



Anna **Fatty Acids Date: 1/8/1999**

Female / Age: 46

This report "MATCHES" clinical observations with the lab test. Elements shown, normal and abnormal, tend to characterize the observation. Highlighted elements are those reported to "MATCH" the characteristics of the clinical observation. Others are NOT matches but are elements in the observation.

No disease pattern matches > 66.0%

Comparison Progress Report

Anna **Fatty Acids Date: 6/28/2004**

Female / Age: 52

A "+" change is toward optimal % Status of zero. A "-" change is away from optimal % Status of zero.

Status % on:	1/8/1999		6/28/2004		+/- change
Docosahexa. C22:6w3	7.24		**-40.00**	**L**	**- 32.76**
Elaidic C18:1w9t	17.39		**50.00**	**H**	**- 32.61**
Lauric C12:0	0.00		**-30.00**	**L**	**- 30.00**
Nervonic C24:1w9	**71.43**	**H**	3.33		+ 68.10
Hexacosanoic C26:0	**104.17**	**H**	**41.43**	**H**	**+ 62.74**
Pentadecanoic C15:0	**-50.00**	**L**	-6.00		+ 44.00

Comparison Report

Anna **Fatty Acids Date: 6/28/2004**

Female / Age: 52

The arrow's length is proportional to change. Left to right is increase. Right to left is decrease.
Green is improvement. Red is decline.

	+/-	Status % on:	1/8/1999		6/28/2004	
-25.00 3.33	+	11-Eicosenoic C20:1w9	**-25.00**	**L**	3.33	
-30.00 -6.25	-	Alpha Linolenic C18:3w3	-6.25		**-30.00**	**L**
		Arachidic C20:0	-8.33		10.00	
		Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**
-20.00 **39.42**	+	Behenic C22:0	**39.42**	**H**	-20.00	
-12.00 0.00	-	Capric C10:0	0.00		-12.00	
		Dihomo-y Lino. C20:3w6	**28.57**	**H**	22.50	
-12.50 3.03	-	Docosadienoic C22:2w6	3.03		-12.50	
-40.00 7.24	-	Docosahexa. C22:6w3	7.24		**-40.00**	**L**
		Docosapenta. C22:5w3	-19.55		**-25.00**	**L**
-34.57 -18.75	-	Eicosadienoic C20:2w6	-18.75		**-34.57**	**L**
-19.12 1.11	+	Eicosapenta. C20:5w3	-19.12		1.11	
17.39 **50.00**	-	Elaidic C18:1w9t	17.39		**50.00**	**H**
-45.00 **25.00**	-	Erucic C22:1w9	**25.00**	**H**	**-45.00**	**L**
-12.50 **35.00**	-	Gamma Linolenic C18:3w6	-12.50		**35.00**	**H**
-33.33 13.33	+	Heptadecanoic C17:0	**-33.33**	**L**	13.33	
41.43 **104.17**	+	Hexacosanoic C26:0	**104.17**	**H**	**41.43**	**H**
-30.00 0.00	-	Lauric C12:0	0.00		**-30.00**	**L**
8.00 16.79	+	Lignoceric C24:0	16.79		8.00	
-40.00 **-25.00**	-	Linoleic C18:2w6	**-25.00**	**L**	**-40.00**	**L**
		Myristic C14:0	-21.88		**25.00**	**H**
-16.00 8.33	-	Myristoleic C14:1w5	8.33		-16.00	
3.33 **71.43**	+	Nervonic C24:1w9	**71.43**	**H**	3.33	
		Nonadecanoic C19:0	-16.67		-10.00	
-27.50 -19.90	-	Oleic C18:1w9	-19.90		**-27.50**	**L**
		Palmitelaidic C16:1w7t	10.71		15.00	
		Palmitic C16:0	-10.26		6.67	
-14.13 **28.00**	-	Palmitoleic C16:1w7	-14.13		**28.00**	**H**
-50.00 -6.00	+	Pentadecanoic C15:0	**-50.00**	**L**	-6.00	
-7.80 18.00	-	Stearic C18:0	-7.80		18.00	
-5.00 16.67	-	Tricosanoic C23:0	-5.00		16.67	
-20.00 -8.33	-	Vaccenic C18:1w7	-8.33		-20.00	
		Total Status Deviation	**27.66**		**21.86**	
		Total Status Skew	**6.21**		**-2.28**	

Panel/Subset Comparison Report

Anna — **Fatty Acids Date: 6/28/2004**

Female / Age: 52

Cardiac Risk	1/8/1999		6/28/2004		+/-
Linoleic C18:2w6	**-25.00**	**L**	**-40.00**	**L**	-
Alpha Linolenic C18:3w3	-6.25		**-30.00**	**L**	-
Gamma Linolenic C18:3w6	-12.50		**35.00**	**H**	-
Dihomo-y Lino. C20:3w6	**28.57**	**H**	22.50		
Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**	
Eicosapenta. C20:5w3	-19.12		1.11		+
Docosapenta. C22:5w3	-19.55		**-25.00**	**L**	
Docosahexa. C22:6w3	7.24		**-40.00**	**L**	-
Lignoceric C24:0	16.79		8.00		+
PSS / PSD	0.80 / 19.11		-3.65 / 26.35		

Gluconeogenesis	1/8/1999		6/28/2004		+/-
Palmitoleic C16:1w7	-14.13		**28.00**	**H**	-
Gamma Linolenic C18:3w6	-12.50		**35.00**	**H**	-
Dihomo-y Lino. C20:3w6	**28.57**	**H**	22.50		
Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**	
Eicosapenta. C20:5w3	-19.12		1.11		+
Hexacosanoic C26:0	**104.17**	**H**	**41.43**	**H**	+
PSS / PSD	20.67 / 35.92		27.26 / 27.26		

Immune Status	1/8/1999		6/28/2004		+/-
Linoleic C18:2w6	**-25.00**	**L**	**-40.00**	**L**	-
Alpha Linolenic C18:3w3	-6.25		**-30.00**	**L**	-
Gamma Linolenic C18:3w6	-12.50		**35.00**	**H**	-
Dihomo-y Lino. C20:3w6	**28.57**	**H**	22.50		
Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**	
Eicosapenta. C20:5w3	-19.12		1.11		+
PSS / PSD	0.45 / 21.41		4.02 / 27.35		

Inflammatory Proc	1/8/1999		6/28/2004		+/-
Oleic C18:1w9	-19.90		**-27.50**	**L**	-
Gamma Linolenic C18:3w6	-12.50		**35.00**	**H**	-
Dihomo-y Lino. C20:3w6	**28.57**	**H**	22.50		
Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**	
Docosapenta. C22:5w3	-19.55		**-25.00**	**L**	
Lignoceric C24:0	16.79		8.00		+
PSS / PSD	5.07 / 22.39		8.08 / 25.58		

Liver Function	1/8/1999		6/28/2004		+/-
Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**	
Behenic C22:0	**39.42**	**H**	-20.00		+
Erucic C22:1w9	**25.00**	**H**	**-45.00**	**L**	-
Docosapenta. C22:5w3	-19.55		**-25.00**	**L**	
Tricosanoic C23:0	-5.00		16.67		-
Lignoceric C24:0	16.79		8.00		+
Hexacosanoic C26:0	**104.17**	**H**	**41.43**	**H**	+
PSS / PSD	28.26 / 35.28		1.66 / 27.37		

Panel/Subset Comparison Report

Anna — **Fatty Acids Date: 6/28/2004**

Female / Age: 52

Monounsaturates	1/8/1999		6/28/2004		+/-
Myristoleic C14:1w5	8.33		-16.00		-
Palmitoleic C16:1w7	-14.13		**28.00**	**H**	-
Vaccenic C18:1w7	-8.33		-20.00		-
Oleic C18:1w9	-19.90		**-27.50**	**L**	-
11-Eicosenoic C20:1w9	**-25.00**	**L**	3.33		+
Erucic C22:1w9	**25.00**	**H**	**-45.00**	**L**	-
Nervonic C24:1w9	**71.43**	**H**	3.33		+
PSS / PSD	10.92 / 27.77		-9.23 / 17.90		

Neurochem Stability	1/8/1999		6/28/2004		+/-
Dihomo-y Lino. C20:3w6	**28.57**	**H**	22.50		
Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**	
Docosahexa. C22:6w3	7.24		**-40.00**	**L**	-
Nervonic C24:1w9	**71.43**	**H**	3.33		+
PSS / PSD	36.06 / 36.06		5.33 / 25.33		

Omega 3/Polys	1/8/1999		6/28/2004		+/-
Alpha Linolenic C18:3w3	-6.25		**-30.00**	**L**	-
Eicosapenta. C20:5w3	-19.12		1.11		+
Docosapenta. C22:5w3	-19.55		**-25.00**	**L**	
Docosahexa. C22:6w3	7.24		**-40.00**	**L**	-
PSS / PSD	-9.42 / 13.04		-23.47 / 24.03		

Omega 6/Polys	1/8/1999		6/28/2004		+/-
Linoleic C18:2w6	**-25.00**	**L**	**-40.00**	**L**	-
Gamma Linolenic C18:3w6	-12.50		**35.00**	**H**	-
Dihomo-y Lino. C20:3w6	**28.57**	**H**	22.50		
Arachidonic C20:4w6	**37.01**	**H**	**35.50**	**H**	
PSS / PSD	5.62 / 20.62		5.22 / 31.98		

Very Long Chains	1/8/1999		6/28/2004		+/-
Behenic C22:0	**39.42**	**H**	-20.00		+
Erucic C22:1w9	**25.00**	**H**	**-45.00**	**L**	-
Docosapenta. C22:5w3	-19.55		**-25.00**	**L**	
Docosahexa. C22:6w3	7.24		**-40.00**	**L**	-
Tricosanoic C23:0	-5.00		16.67		-
Lignoceric C24:0	16.79		8.00		+
Nervonic C24:1w9	**71.43**	**H**	3.33		+
Hexacosanoic C26:0	**104.17**	**H**	**41.43**	**H**	+
PSS / PSD	29.94 / 36.07		-7.57 / 24.93		